Mesa Laboratories MLAB Business Segments
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| Revenue by Business | |||||
| Biopharmaceutical Development | $48.63M-0.2% | $48.73M+19.7% | $40.71M-14.0% | $47.37M+3.9% | |
| Clinical Genomics | $45.39M-3.6% | $47.08M-10.5% | $52.59M-15.6% | $62.3M+89.7% | |
| Revenue by Product | |||||
| Service | $45.74M+7.4% | $42.58M+8.1% | $39.39M+1.9% | $38.65M+10.7% | |
| Revenue by Geography | |||||
| CN | $20.45M-19.2% | $25.31M+1.5% | $24.93M-3.3% | $25.8M+56.2% | |
| Other | $111.79M+12.9% | $99.05M+16.7% | $84.86M+11.7% | $76M+10.5% | |
| US | $116.9M+0.2% | $116.62M+9.6% | $106.4M-9.3% | $117.28M+18.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Mesa Laboratories break its business down?
- Mesa Laboratories (MLAB) reports revenue by business across 3 parts — Biopharmaceutical Development, Calibration Solutions and Clinical Genomics. Each is extracted from the segment footnotes and tracked over time.
- Where does Mesa Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Mesa Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
